Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Akebia Therapeutics posts robust Q4 results, eyes expansion opportunities

Akebia Therapeutics showcased a strong performance in Q4 2022, highlighting revenue growth, regulatory progress, and strategic initiatives. The company faces challenges in regulatory processes and funding but is well-positioned to capitalize on opportunities for growth and innovation.

Akebia Therapeutics excels in Q1 2023, faces regulatory challenges

Akebia Therapeutics demonstrated strong performance in Q1 2023 with key achievements in product approvals and clinical study results, while also addressing revenue challenges and cost management.
The company faces challenges related to regulatory compliance and revenue decline but has opportunities to explore new therapeutic applications and strategic partnerships for growth.
Overall, Akebia's proactive approach to addressing challenges and pursuing opportunities positions it well for future success in the competitive biopharmaceutical market.

Akebia Therapeutics advances vadadustat globally, eyes U.S. launch in 2024

Akebia Therapeutics showcased operational progress and financial stability during the Q2 earnings call, emphasizing vadadustat's global potential.
While facing regulatory challenges and competitive pressures, the company's strategic partnerships and leadership confidence signal growth opportunities.
Analysts' inquiries highlighted areas for improvement, suggesting a need for clearer communication and strategic clarity in key operational areas.
Overall, Akebia remains focused on advancing vadadustat towards potential U.S. approval, positioning for future growth and market success.

Akebia Therapeutics reports strong Q3 earnings and readies for vadadustat launch

Akebia Therapeutics is poised for the potential launch of vadadustat with strong financial performance and a well-prepared commercial infrastructure.
The company faces challenges in pricing strategies and market competition but has opportunities to capture a significant share of the anemia treatment market.
Overall, Akebia Therapeutics remains focused on delivering value to patients and shareholders through vadadustat's potential success in the U.S. market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akebia Therapeutics (AKBA) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat. The post Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?

Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?

Quoin Pharmaceuticals Ltd

Ricebran Technologies

Shift Technologies

Penny stocks under $1 to watch. The post Best Penny Stocks To Buy Right Now?

Best Penny Stocks To Buy Right Now? 4 To Watch Under $1

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday.

Akebia Therapeutics And 20 Stocks Moving Premarket

Micron Technology

Accolade

Costco

Hillenbrand

Some of the stocks that may grab investor focus today are: Micron Technology Inc (NASDAQ: MU) reported upbeat financial results for its third quarter, but issued weak guidance for its fourth quarter. Micron shares dropped 1.4% to $54.50 in the after-hours trading session.

Micron, Akebia Therapeutics And 3 Stocks To Watch Heading Into Friday

Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with Otsuka Pharmaceutical. As a result of the termination of the agreements, Akebia.

Why Akebia Therapeutics Stock Is Soaring After Hours

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia Akebia to assume responsibility for regulatory review processes previously led by Otsuka CAMBRIDGE, Mass. , June 30, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd.

Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka

AKBA stock is up big, but the lack of news is concerning considering that Akebia Therapeutics already faces a regulatory setback. The post Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News appeared first on InvestorPlace.

Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News

Digital Brands Group Inc

Exela Technologies

Here's what you need to know about trading penny stocks today The post What to Know About Trading Penny Stocks on June 13th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Trading Penny Stocks on June 13th

Akebia Therapeutics Inc (NASDAQ: AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated.

Why Are Akebia Therapeutics Shares Falling Today?

New York, New York--(Newsfile Corp. - May 13, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the "Class Period"), of the important May 13, 2022 lead plaintiff deadline.SO WHAT: If you purchased Akebia securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

AKBA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBA

NEW YORK , May 13, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/akebia-therapeutics-inc-loss-submission-form/?id=27147&from=4 The lawsuit seeks to recover losses for shareholders who purchased Akebia between June 28, 2018 and September 2, 2020.

AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders of a Lead Plaintiff Deadline of May 13, 2022

NEW YORK , May 12, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Akebia investors who were adversely affected by alleged securities fraud between June 28, 2018 and September 2, 2020.

AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

New York, New York--(Newsfile Corp. - May 11, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/akebia-therapeutics-inc-loss-submission-form?prid=27127&wire=5

AKBA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Akebia Therapeutics, Inc.

New York, New York--(Newsfile Corp. - May 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the "Class Period"), of the important May 13, 2022 lead plaintiff deadline.SO WHAT: If you purchased Akebia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

AKBA FINAL DEADLINE FRIDAY: GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBA

New York, New York--(Newsfile Corp. - May 11, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws.Class Period: June 28, 2018 to September 2, 2020Lead Plaintiff Deadline: May 13, 2022No obligation or cost to you.Learn more about your recoverable losses in AKBA:https://www.kleinstocklaw.com/pslra-1/akebia-therapeutics-inc-loss-submission-form?id=27104&from=5

AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - May 11, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join...

Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action Deadline: May 13, 2022

Matterport

Nektar Therapeutics

Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 11th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on May 11th

NEW YORK , May 11, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc.. Shareholders who purchased shares of AKBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 13, 2022 - (NASDAQ: AKBA)

New York, New York--(Newsfile Corp. - May 10, 2022) - Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit.The lawsuit on behalf of Akebia investors has been commenced in the the United States District Court for the Eastern District of New York. Affected investors purchased or otherwise acquired certain Akebia Therapeutics, Inc. securities between June 28, 2018 and September 2, 2020. Follow...

Akebia Class Action: Levi & Korsinsky Reminds Akebia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2022 - AKBA

NEW YORK , May 10, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the Company violated federal securities laws. Class Period: June 28, 2018 to September 2, 2020 Lead Plaintiff Deadline: May 13, 2022 No obligation or cost to you.

AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders

Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Mercedes Carrasco - Director, Corporate Communications John Butler - CEO, President & Director David Spellman - SVP, CFO & Treasurer Conference Call Participants Allison Bratzel - Piper Sandler & Co. Mara Goldstein - Mizuho Securities Antonio Arce - H.C. Wainwright & Co. Rohit Bhasin - Needham Operator Ladies and gentlemen, thank you for standing by, and welcome to the Akebia First Quarter 2022 Financial Results Conference Call.

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2022 Results - Earnings Call Transcript

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates

Net Auryxia® (ferric citrate) product revenue of $41.4M, a 36% increase over Q1 2021 2022 Net Auryxia product revenue guidance of $165 - $170M Outlines refined strategic focus to deliver shareholder value Akebia to host conference call on Monday, May 9 at 4:30 p.m. ET CAMBRIDGE, Mass.

Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting th

Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages May 13, 2022 Deadline

NEW YORK , May 9, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the "Class Period"), of the important May 13, 2022 lead plaintiff deadline. SO WHAT: If you purchased Akebia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA

News for Akebia Therapeutics Stock (AKBA)